Statement of Organization, Functions, and Delegations of Authority, 43190-43193 [2010-17794]
Download as PDF
43190
Federal Register / Vol. 75, No. 141 / Friday, July 23, 2010 / Notices
5. How can the SACWIS regulations
be modified to encourage flexibility and
support different practice models while
ensuring standardized data is available
as needed?
ACF will consider the comments after
the comment period closes to further
assess SACWIS regulations.
Dated: July 15, 2010.
Bryan Samuels,
Commissioner, Administration on Children,
Youth and Families.
[FR Doc. 2010–18038 Filed 7–22–10; 8:45 am]
BILLING CODE 4184–25–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Statement of Organization, Functions,
and Delegations of Authority
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 75 FR 34465, dated
June 9, 2010) is amended to reflect the
substructure of the National Center for
Emerging and Zoonotic Infectious
Diseases, Office of Infectious Diseases,
Centers for Disease Control and
Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
After the title and functional statements for
the National Center for Immunization and
Respiratory Diseases (CVG), insert the
following:
National Center for Emerging and Zoonotic
Infectious Diseases (CVL). The National
Center for Emerging and Zoonotic Infectious
Diseases (NCEZID) works to prevent and
control a broad range of infectious diseases
through public leadership, partnerships,
science, and systems. In carrying out these
activities, NCEZID: (1) Works collaboratively
across CDC and with external partners to
conduct, coordinate, support, and evaluate
public health efforts to prevent and minimize
morbidity and mortality due to infectious
diseases, promoting a One Health approach
involving the interface of animal, human,
and environmental factors; (2) develops,
evaluates, and advances science, programs,
management, and operations toward meeting
the agency’s infectious disease related
mission and goals; (3) conducts
epidemiologic and laboratory science and
applied research aimed at identifying risk
factors and disease burdens and developing
and implementing public health programs,
practices, and policies for infectious disease
VerDate Mar<15>2010
15:15 Jul 22, 2010
Jkt 220001
prevention and control; (4) works with
domestic and global partners to provide
technical and subject matter expertise in
responding to outbreaks and in establishing,
maintaining, and evaluating disease control
and prevention programs; (5) supports a
broad range of cross-cutting and collaborative
programs aimed at enhancing public health
capacity at the local, State, and national
levels; (6) works to improve the quality and
safety of healthcare through efforts to reduce
healthcare associated infections and
antimicrobial resistance and to ensure the
safety of medical products, including
vaccines; (7) conducts activities to improve
the safety of food and water and reduce
related enteric illnesses; (8) administers a
national quarantine program to prevent U.S.
importation and spread of infectious
diseases; (9) works with CDC colleagues and
external partners to improve public health
preparedness at the local, State, and national
levels; and (10) works to increase public
health prevention efforts for populations at
increased risk for infectious diseases.
Office of the Director (CVL1). (1) Provides
leadership in developing, prioritizing,
advancing, and evaluating the center’s
science, programs, management, and
operations toward meeting agency mission
and goals; (2) advises the CDC Director and
Deputy Director for Infectious Diseases on
priority issues affecting the center; (3)
identifies and facilitates synergies within
NCEZID, across CDC, and with external
partners for addressing emerging and
zoonotic infectious diseases domestically and
globally; (4) enhances collaborations and
partnerships across multiple disciplines,
including human and animal health; (5)
ensures scientific quality and ethical and
regulatory compliance of center activities; (6)
provides leadership, guidance, and technical
assistance on policy and communication
issues affecting the center; (7) serves as
liaison with CDC counterparts, CDC/OD,
other government agencies, and external
partners on policy, program, legislative,
communication, and budgetary issues related
to NCEZID; (8) recruits and supports a strong
center-wide workforce and builds leadership
at the division and branch levels; (9) ensures
that programmatic goals are achieved with
measurable impact; and (10) ensures effective
administrative services for NCEZID as well as
effective cross-cutting scientific and program
services for all CDC’s infectious disease
national centers.
Food Safety Office (CVL12). (1) Provides
leadership in preventing and controlling
foodborne illness by coordinating related
activities within CDC and with other local,
State, Federal, and international
organizations; (2) directs the activities related
to development of long-term NCEZID, OID,
and CDC strategies, policies, and budgets for
foodborne disease prevention activities; (3)
allocates and tracks interagency resources
within CDC for foodborne disease
surveillance, outbreak response, applied
research, education and training; (4)
administers and tracks resources for
foodborne disease prevention and control
activities of State and local health
departments and other organizations; (5)
represents NCEZID and CDC programs and
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
prevention policies in meetings with
governmental, non-governmental, private,
and international organizations; (6) reviews,
prepares, and coordinates congressional
testimony and briefing documents related to
foodborne diseases, and analyzes
programmatic and policy implications of
legislative proposals; and (7) provides
direction and administrative support to the
World Health Organization (WHO)
Collaborating Center for Foodborne Disease
Surveillance.
Division of Foodborne, Waterborne, and
Environmental Diseases (CVLB). The mission
of the Division of Foodborne, Waterborne,
and Environmental Diseases (DFWED) is to
improve public health nationally and
internationally through the prevention and
control of disease, disability, and death
caused by foodborne, waterborne, and
environmentally-transmitted infections. In
carrying out its mission, DFWED: (1)
Conducts surveillance, investigations, and
studies of foodborne bacterial diseases,
waterborne bacterial and parasitic diseases,
and mycotic diseases to define disease
etiology and develop effective methods for
diagnosis, prevention, and control; (2)
conducts or participates in clinical, field, and
laboratory research to develop, evaluate, and
improve laboratory methodologies, materials,
and therapeutic practices used for
environmental detection, diagnosis,
treatment, investigation, and control of
foodborne bacterial diseases, waterborne
bacterial and parasitic diseases, and mycotic
diseases; (3) fosters and coordinates
environmental microbiology research
activities at CDC through the Environmental
Microbiology Workgroup, partnerships, and
advocacy activities to promote research on
preventing infectious disease transmission
from the environment to humans; (4)
provides epidemic aid and epidemiologic
consultation, upon request, to State and local
health departments, other Federal agencies,
and national and international health
organizations; (5) provides reference/
diagnostic services for foodborne bacterial
diseases, waterborne bacterial and parasitic
diseases, and mycotic diseases to State and
local health departments, other Federal
agencies, and national and international
health organizations; (6) provides scientific
and technical assistance to other CDC
components when the work requires unique
expertise or specialized equipment not
available in other components; (7) provides
intramural and extramural technical
expertise and assistance in professional
training and proficiency testing activities; (8)
serves as appropriately designated national
and international reference centers for
various foodborne bacterial diseases,
waterborne bacterial and parasitic diseases,
and mycotic diseases and disease groups; and
(9) develops clear health promotion
strategies, campaigns, and messages to
promote prevention.
Office of the Director (CVLB1). (1) Directs
and manages the programs and activities of
DFWED; (2) provides leadership and
guidance on policy, program planning and
development, program management, and
operations; (3) coordinates or assures
coordination with the appropriate CDC and
E:\FR\FM\23JYN1.SGM
23JYN1
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Federal Register / Vol. 75, No. 141 / Friday, July 23, 2010 / Notices
NCEZID offices on administrative and
program matters; (4) reviews, prepares, and
coordinates congressional testimony and
briefing documents related to foodborne
bacterial diseases, waterborne bacterial and
parasitic diseases, and mycotic diseases, and
analyzes programmatic and policy
implications of legislative proposals; (5)
represents CDC and NCEZID programs and
prevention policies in meetings with
governmental, private, and international
organizations; (6) advises CDC and NCEZID
on policy matters concerning DFWED
programs and activities; (7) provides
statistical methodology and participates in
the DFWED’s outbreak investigations and
disease reporting systems for ongoing
surveillance; (8) develops new methods or
adapts existing methods for statistical
applications in epidemiologic or laboratory
research studies for the division; (9) provides
statistical consultation for epidemiologic and
laboratory research studies conducted by the
division; (10) assists researchers with
statistical aspects of report writing and
prepares statistical portions of papers,
protocols, and reports written by staff of the
division, and trains division professional
staff in statistical methods; (11) provides
oversight for CDC involvement in the WHO
Global Foodborne Infections Network and
training in food, water, and zoonotic
infection control and prevention; and (12)
provides subject matter expertise on
environmental research, and promotes and
coordinates related research activities at CDC
and with collaborative partners.
Division of Global Migration and
Quarantine (CVLC). (1) Administers a
national quarantine program to protect the
U.S. against the introduction of diseases from
foreign countries and the transmission of
communicable disease between states; (2)
administers an overseas program for the
medical examination of immigrants, refugees,
and as necessary, other migrant populations
destined for legal entry to the U.S., with
inadmissible health conditions that would
pose a threat to public health and impose a
burden on public health and hospital
facilities; (3) conducts surveillance, research,
and prevention programs to prevent
minimize morbidity and mortality among the
globally mobile populations entering and
leaving the U.S.; (4) maintains liaison with
other Federal agencies, State and local health
departments, and other stake holders, and
provides information on global migration and
quarantine matters to them; (5) provides
liaison with international health
organizations and participates in the
development of international agreements
affecting quarantine; (6) evaluates and
provides technical support on the
development and enforcement of policies
necessary for implementation of Federal
quarantine authority; (7) conducts studies to
provide new information about health
hazards abroad, measures for their
prevention, and the potential threat of
disease introduction into the U.S.; and (8)
provides logistic support to other programs of
the CDC in the distribution of requested
biological agents and movement of biological
specimens through U.S. ports of entry.
Office of the Director (CVLC1). (1)
Manages, directs, and coordinates the
VerDate Mar<15>2010
15:15 Jul 22, 2010
Jkt 220001
activities of the division; (2) provides
leadership in development of division policy,
program planning, implementation, and
evaluation; (3) identifies needs and resources
for new initiatives and assigns
responsibilities for their development; (4)
coordinates liaison with other Federal
agencies, State and local health departments,
and interested industries; (5) coordinates
liaison with international health
organizations; and (6) reviews and evaluates
all administrative services for both
headquarters and quarantine stations and
provides policy procedures and guidance on
such matters.
Division of Healthcare Quality Promotion
(CVLD). The mission of the Division of
Healthcare Quality Promotion (DHQP) is to
protect patients; protect healthcare
personnel; and promote safety, quality, and
value in both national and international
healthcare delivery systems. In carrying out
its mission, DHQP: (1) Measures, validates,
interprets, and responds to data relevant to
healthcare processes and outcomes,
healthcare-associated infections,
antimicrobial resistance, adverse drug events,
and other related adverse events or medical
errors in healthcare affecting patients and
healthcare personnel; (2) investigates and
responds to emerging infections and related
adverse events among patients and
healthcare providers, or others associated
with the healthcare environment; (3)
collaborates with academic and public health
partners to design, develop, and evaluate the
efficacy of interventions for preventing
infections and reducing antimicrobial
resistance, and related adverse events or
medical errors; (4) develops and disseminates
evidence-based guidelines and
recommendations to prevent and control
healthcare-associated infections/
antimicrobial resistance, and related adverse
events or medical errors; (5) promotes the
nationwide implementation of Healthcare
Infection Control Practices Advisory
Committee (HICPAC) recommendations and
other evidence based interventions to prevent
healthcare-associated infections,
antimicrobial resistance, and related adverse
events or medical errors among patients and
healthcare personnel; evaluates the impact of
these recommendations and interventions
across the spectrum of healthcare delivery
sites; (6) monitors vaccine safety and
conducts scientific research to evaluate the
safety of all currently available and new
vaccines; (7) develops, implements, and
evaluates the effectiveness and impact of
interventions to prevent transmission of
healthcare-associated human
immunodeficiency virus (HIV) and other
bloodborne pathogen infections; (8) develops
and evaluates diagnostic instruments and
novel laboratory tests to detect and
characterize antimicrobial-resistant bacterial
pathogens and the infections that they cause;
(9) promotes high standards of water quality
in healthcare settings and tests and assures
the water quality for CDC’s infectious disease
laboratories; (10) conducts epidemiologic,
and basic and applied laboratory research to
identify new strategies to prevent infections/
antimicrobial resistance, and related adverse
events or medical errors, especially those
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
43191
associated with medical or surgical
procedures, indwelling medical devices,
contaminated products, dialysis, and water;
(11) establishes evidence-base for surface
decontamination by performing laboratory
research on methods for surface sampling
detection of selected organisms related to
preventing healthcare associated infections;
(12) serves as the National Reference
Laboratory for the identification and
antimicrobial susceptibility testing of
staphylococci, anaerobic bacteria, nontuberculous mycobacterial, and those gramnegative bacilli causing healthcare associated
infections; (13) develops and maintains the
National Healthcare Safety Network (NHSN),
a tool for monitoring healthcare-associated
infections, measuring healthcare outcomes
and processes, and monitoring healthcare
worker vaccination and selected health
measures in healthcare facilities; (14)
continually assesses rates of infections
caused by resistant-bacteria in the U.S.
through active surveillance, review of
national healthcare data sets, and laboratory
surveillance programs; (15) promotes the
integration of the healthcare delivery system
in Federal/State/local public health
preparedness planning; (16) coordinates
activities, guidance, and research related to
infection control across the agency and with
national and international partners; (17)
collaborates with other CDC Centers/
Institute/Offices (CIO) and partners to assure
quality clinical microbiology laboratory
practices through proficiency testing,
educational programs, and training of
personnel; (18) trains Epidemic Intelligence
Service Officers and other trainees; (19)
coordinates antimicrobial resistance
activities at CDC; (20) works in a national
leadership capacity with public and private
organizations to enhance antimicrobial
resistance prevention and control,
surveillance and response, and applied
research; and (21) coordinates blood, organ,
and other tissue safety at CDC.
Office of the Director (CVLD1). (1)
Manages, directs, and coordinates the
activities of the DHQP; (2) provides
leadership and guidance on policy,
communications/media, program planning
and development, program management, and
operations; (3) provides DHQP-wide
administrative and program services and
coordinates or ensures coordination with the
appropriate CIOs and CDC staff offices on
administrative and program matters; (4)
provides liaison with other governmental
agencies, international organizations, and
other outside groups; (5) coordinates, in
collaboration with the appropriate CIO and
CDC components, global health activities
relating to the prevention of healthcareassociated infections/antimicrobial
resistance, and related adverse events or
medical errors; (6) coordinates activities,
guidance, emergency response, and research
related to infection control in healthcare
settings across the agency and with national
and international partners; (7) works with
other Federal agencies, State governments,
medical societies, and other public and
private organizations to promote
collaboration and to integrate healthcare
preparedness in Federal/State/local public
E:\FR\FM\23JYN1.SGM
23JYN1
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
43192
Federal Register / Vol. 75, No. 141 / Friday, July 23, 2010 / Notices
health preparedness planning; (8) oversees
the coordination of antimicrobial resistance
activities at CDC; (9) represents CDC as cochair of the Federal Interagency Task Force
on Antimicrobial Resistance; (10) coordinates
with other agencies, State governments,
medical societies, and other public and
private organizations to enhance
antimicrobial resistance prevention and
control, surveillance and response, and
applied research; (11) leads CDC’s activities
on blood, organ, and other tissue safety; (12)
represents CDC on the Advisory Committee
on Blood Safety and Availability and the
Advisory Committee on Organ
Transplantation; (13) works with other
Federal agencies, State governments, and
other public and private organizations to
enhance blood, organ, and other tissue safety
through coordination of investigation,
prevention, response, surveillance, applied
research, health communication, and public
policy; (14) provides program and
administrative support for HICPAC; and (15)
advises the Director, NCEZID, on policy
matters concerning DHQP activities.
Immunization Safety Office (CVLD12). (1)
Assesses the safety of vaccines received by
children, adolescents and adults; (2)
coordinates vaccine safety activities at CDC;
(3) monitors safety of new and currently
available vaccines; (4) coordinates and
maintains the Vaccine Adverse Event
Reporting System and Vaccine Safety
Datalink; (5) leads CDC’ s scientific research
to evaluate the safety of all currently
available and new vaccines; and (6) works
with other Federal agencies, State
governments, and other public and private
organizations to assess and promote the
safety of vaccines.
Division of High-Consequence Pathogens
and Pathology (CVLE). The Division of HighConsequence Pathogens and Pathology
(DHCPP) maximizes public health and safety
nationally and internationally through the
diagnosis, prevention, and control of disease,
disability, and death caused by suspected
and known viral, bacterial, prion, and related
infections. In carrying out its mission,
DHCPP: (1) Conducts surveillance,
investigations, and studies of viral and
bacterial diseases, including bioterrorism
agents, as well as of transmissible spongiform
encephalopathies, or prion diseases, and
severe diseases of unknown, but suspected
infectious etiology, to define their etiology
and epidemiology, and to develop effective
methods for diagnosis, treatment, control,
and prevention; (2) conducts or participates
in clinical, field, and laboratory research to
develop, evaluate, and improve laboratory
methods, materials, and therapeutic practices
used for diagnosis, treatment, control, and
prevention of viral, bacterial, and prion
diseases, including bioterrorism agents; (3)
conducts research on virus and bacterial
transmission to develop effective control and
prevention strategies and on vaccine
effectiveness to assess prevention potential;
(4) conducts laboratory, clinical, and
epidemiologic studies of highly hazardous
disease agents that require biosafety level 3
or biosafety level 4 security for their safe
handling; (5) conducts ecological studies to
develop and evaluate disease control and
VerDate Mar<15>2010
15:15 Jul 22, 2010
Jkt 220001
prevention measures; (6) provides epidemic
aid, epidemiologic consultation, reference
and diagnostic services, and technical
assistance to State and local health
departments, other Federal agencies, and
national and international health
organizations; (7) provides scientific and
technical assistance to other CDC
components when the work requires unique
expertise or specialized equipment not
available in other components; (8) provides
routine and specialized laboratory training in
the diagnosis, isolation, and characterization
of viral and bacterial agents to personnel
from State and local health departments and
other national and international
organizations; (9) provides training
opportunities for EIS officers and others in
CDC sponsored programs, including
postgraduate students, postdoctoral fellows,
and other public health and laboratory
scientists; (10) provides expert pathological
support for various infectious diseases to
other groups at CDC, State and local health
departments, other Office of Infectious
Diseases (OID) components, and national and
international organizations; and (11) serves
as appropriately designated national and
WHO Collaborating Centers for viral and
bacterial diseases.
Office of the Director (CVLE1). (1) Directs
and manages the programs and activities of
DHCPP; (2) provides leadership and guidance
on policy, program planning and
development, program management, and
operations; (3) coordinates or assures
coordination with the appropriate CDC, OID,
and NCEZID offices on administrative and
program matters; (4) reviews, prepares, and
coordinates congressional testimony and
briefing documents related to highconsequence viral, bacterial, and prion
diseases, and analyzes programmatic and
policy implications of legislative proposals;
(5) represents CDC, OID, and NCEZID
programs and prevention policies in
meetings with other governmental, private,
and international organizations; (6) serves as
CDC, OID, and NCEZID’s primary internal
and external communications contact
regarding high consequence viral, bacterial,
and prion disease issues; and (7) advises
CDC, OID, and NCEZID on policy matters
concerning DHCPP programs and activities.
Prion and Public Health Office (CVLE12).
(1) Serves as the lead Federal office for
monitoring the occurrence of human prion
disease in the U.S.; (2) conducts
epidemiological investigations, studies, and
multiple methods of surveillance to increase
understanding of human prion diseases and
selected diseases of unknown etiology (e.g.,
Kawasaki syndrome) for the purpose of
informing disease control policies; (3)
facilitates the study of brain autopsies by
skilled pathologists of clinically diagnosed
and suspected cases of human prion disease
in the U.S. to enable early recognition of the
emergence of any new prion disease (e.g.,
variant Creutzfeldt-Jacob Disease and
possibly human chronic wasting disease); (4)
provides prion disease consultations to
clinicians, State and local health
departments, other Federal agencies, and
national and international organizations,
including epidemic aid support as needed;
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
(5) disseminates information and advice to
the public on preventing or reducing the
negative public impacts of prion diseases and
selected diseases of unknown etiology; (6)
serves as a DHCPP statistical analysis unit,
collaborating with and supporting studies,
investigations, and surveillance activities of
epidemiologists and laboratory researchers;
(7) provides statistical consultations and
collaborates with researchers on local,
national, and international public health
morbidity and mortality studies that require
expertise in manipulating and understanding
large public health datasets; and (8) provides
statistical and epidemiologic training
opportunities for EIS officers and other
personnel in CDC sponsored programs.
One Health Office (CVLE13). (1) Serves as
the agency focal point and provides the
programmatic home for activities on One
Health, an integrated approach to optimizing
human and animal health that considers the
interrelatedness among humans, animals,
and their environments; (2) builds and
organizes a portfolio of One Health activities,
plans, and accomplishments and leads the
efforts to promote and accomplish the
activities through NCEZID and CDC programs
and partnerships; (3) builds partnerships and
facilitates collaboration both within and
external to CDC; (4) manages and allocates
NCEZID extra-budgetary resources from the
Department of State/USAID, the Department
of Defense/BTEP, the National Center for
Environmental Health/Climate Change, and
others, as appropriate; and (5) facilitates the
exchange of information and enhances
communication across disciplines by
sponsoring visiting scientists and fellows,
lectures, and meetings.
Division of Preparedness and Emerging
Infections (CVLG). The Division of
Preparedness and Emerging Infections (DPEI)
works to build and strengthen public health
capacity by enhancing the ability of CDC and
its public health partners to prepare for,
prevent, and respond to infectious diseases,
including outbreaks, bioterrorism, and other
public health emergencies, through crosscutting and specialized programs, technical
expertise, and public health leadership. In
carrying out these activities, the DPEI: (1)
Advocates for CDC programs, health
departments, and other partners on issues
related to emerging infections, bioterrorism,
and public health resources; (2) develops and
implements infectious disease surveillance,
laboratory, and capacity building activities in
collaboration with other CDC programs and
external partners; (3) works with infectious
disease programs on processes for
developing, awarding, managing, and
evaluating infectious disease grants and
cooperative agreements; (4) provides
scientific and programmatic leadership, as
well as management, administrative, and
technical support for broad infectious disease
cooperative agreements such as the Emerging
Infections Program (EIPs) and the
Epidemiology and Laboratory Capacity for
Infectious Diseases (ELC) program; (5)
collaborates across CDC and with national
and international partners to address the
scientific and response planning and
preparedness issues for bioterrorism,
emerging infections, and other infectious
E:\FR\FM\23JYN1.SGM
23JYN1
WReier-Aviles on DSKGBLS3C1PROD with NOTICES
Federal Register / Vol. 75, No. 141 / Friday, July 23, 2010 / Notices
disease emergencies; (6) provides the
agency’s initial rapid response capabilities
(including 24 hour on-call emergency
response coordination and epidemiologic
and laboratory support) for bioterrorism and
other infectious disease public health
emergencies; (7) conducts, supports, and
evaluates activities aimed at identifying and
reducing risk factors for infectious diseases
among residents of the Arctic and Subarctic
regions; (8) maintains primary responsibility
for development and management of the
nation’s Laboratory Response Network (LRN),
including supporting the development,
deployment, and quality control of diagnostic
reagents for the LRN laboratories; (9) defines
and promotes good laboratory practice
standards, including providing consultation
and training and improving communication
and collaborations among public and private
sector laboratories nationally and
internationally; (10) serves as a primary
screening laboratory for CDC for specimens
that may contain threat agents; (11) analyzes
the economic impact of infectious diseases in
collaboration with other CDC infectious
disease programs and collaborators outside
the agency; (12) leads and coordinates
infectious disease fellowships and training
programs; (13) provides technical assistance
and training on biosafety/biosecurity and
bioterrorism agent detection and response to
internal and external partners, including
assistance with related public health and law
enforcement investigations and planning for
high profile national and international
events; and (14) assists in medical
countermeasures response and utilization
coordination.
Office of the Director (CVLG1). (1)
Manages, directs, and coordinates the
activities of DPEI; (2) provides leadership
and guidance on division policy, program
planning, program management, and
operations; (3) provides division-wide
administrative and program services and
ensures coordination with the appropriate
CIO or staff offices on administrative and
program matters; (4) provides liaison with
other governmental agencies, international
organizations, academic institutions and
other outside groups; (5) ensures
coordination of cross-cutting division
activities with appropriate NCEZID divisions,
the Office of Public Health Preparedness and
Response, the Office of Surveillance,
Epidemiology, and Laboratory Services
(OSELS), and other CDC CIOs and offices;
and (6) advises the NCEZID Director, the
Deputy Director for Infectious Diseases, and
leadership in other CDC units on division
policy matters.
Division of Scientific Resources (CVLH).
The Division of Scientific Resources (DSR)
provides products, services, and specialized
expertise to CDC staff and activities in
support of research and service activities. In
carrying out its mission, DSR: (1) Provides
animals, laboratory supplies, animal and
human blood products, glassware,
mammalian tissue cultures, microbiological
media, special reagents, and other laboratory
materials in support of research and service
activities to laboratories and investigators at
CDC; (2) develops and implements applied
research programs to expand and enhance
VerDate Mar<15>2010
15:15 Jul 22, 2010
Jkt 220001
the use of animal models necessary to
support research and diagnostic programs
and to improve breeding and husbandry
procedures; (3) conducts applied research in
cell biology and in the expansion of tissue
culture technology as a research and
diagnostic tool for infectious disease
activities; (4) provides services for laboratory
investigators in protein and DNA synthesis
and sequencing, genomic sequencing,
microarrays, proteomics, and molecular
modeling; (5) maintains a bank of serum and
other biological specimens of
epidemiological and special significance to
CDC’s research and diagnostic activities; (6)
obtains and distributes experimental and
orphaned vaccines, drugs, antisera,
antitoxins, and immune globulins; (7)
manages and distributes the inventory,
maintains the computerized system database,
and provides general technical service
support for the dispensing, lyophilizing,
capping, and labeling of CDC reference
reagents; (8) receives, triages, processes, and
distributes specimens to CDC laboratories for
reference diagnostic testing, research studies,
and epidemics and reports diagnostic test
results to submitting organizations; (9)
manages all CDC exports and ensures
compliance with regulations and serves as
CDC liaison with Department of Commerce
for export related issues; (10) produces and
distributes specialized reagents and kits for
the detection of select agents to members of
the LRN; (11) provides services and expertise
in development of quality systems to support
compliance with the Food and Drug
Administration regulations on production,
distribution, and use of laboratory diagnostic
reagents; (12) provides liaison activities,
resources, and expertise for inquiries related
to animals and zoonotic diseases; and (13)
provides a centralized activity for tracking
requests for and distributing select agents to
investigators outside of CDC in compliance
with Federal regulations.
Office of the Director (CVLH1). (1)
Manages, directs, and coordinates the
activities of DSR; (2) provides leadership and
guidance on policy, budget, program
planning and development, program
management, and operations; (3) provides
DSR wide administrative and program
services and coordinates or ensures
coordination with the appropriate CIOs OID,
and CDC staff offices on administrative and
program matters; (4) provides liaison with
other governmental agencies, international
organizations, and other outside groups; (5)
coordinates, in collaboration with the
appropriate CIOs, OID, and CDC components,
laboratory activities relating to support of
outbreak investigations or laboratory-based
research including but not limited to
specimen management, biological reagents,
and laboratory supplies; (6) maintains a
formulary of investigational and licensed
drugs and biologicals that are distributed to
approved physicians for the prevention,
control, and/or treatment of rare, tropical, or
exceptional diseases; (7) collaborates with
CDC and external partners on research
related to STD transmitted infections as
chronic infectious diseases; and (8) advises
the Director, NCEZID, on policy matters
concerning DSR activities.
PO 00000
Frm 00057
Fmt 4703
Sfmt 9990
43193
Division of Vector-Borne Diseases (CVLJ).
(1) Conducts surveillance, investigations, and
studies of vector-borne viral, rickettsial, and
bacterial diseases to define disease etiology
and to develop effective methods and
strategies for diagnosis, prevention, and
control; (2) conducts investigations on the
biology, ecology, and control of arthropod
vectors of viral, rickettsial, and bacterial
diseases as a basis for development of new
and/or modification of existing measures for
more effective prevention and control; (3)
conducts or participates in clinical, field, and
laboratory studies to develop, evaluate, and
improve laboratory methods, materials, and
therapeutic practices used for diagnosis,
prevention, and treatment of vector-borne
infectious diseases; (4) provides epidemic aid
and epidemiologic consultation, upon
request, to State and local health
departments, other Federal agencies, and
national and international health
organizations; (5) provides reference/
diagnostic services for vector-borne viral,
rickettsial, and bacterial diseases to State and
local health departments, other Federal
agencies, and national and international
health organizations; (6) conducts research
and collaborates on development and
evaluation of vaccines; (7) provides scientific
and technical assistance to other CDC
components when the work requires unique
expertise or specialized equipment not
available in other components; (8) provides
intramural and extramural technical
expertise and assistance in professional
training activities; and (9) serves as
designated national and international
reference centers for vector-borne viral,
rickettsial, and bacterial diseases.
Office of the Director (CVLJ1). (1) Directs
and manages the programs and activities of
the Division of Vector-Borne Diseases
(DVBD); (2) provides leadership and
guidance on policy, program planning and
development, program management, and
operations; (3) coordinates or assures
coordination with the appropriate CDC, OID,
and NCEZID offices on administrative and
program matters; (4) reviews, prepares, and
coordinates congressional testimony and
briefing documents related to vector-borne
infectious diseases, and analyzes
programmatic and policy implications of
legislative proposals; (5) represents CDC and
NCEZID in meetings with other
governmental, private, and international
organizations; (6) serves as CDC and
NCEZID’s primary internal and external
communications contact regarding vectorborne infectious disease issues; and (7)
advises CDC and NCEZID on policy matters
concerning DVBD programs and activities.
Dated: July 9, 2010.
William P. Nichols,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2010–17794 Filed 7–22–10; 8:45 am]
BILLING CODE 4160–18–M
E:\FR\FM\23JYN1.SGM
23JYN1
Agencies
[Federal Register Volume 75, Number 141 (Friday, July 23, 2010)]
[Notices]
[Pages 43190-43193]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-17794]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Statement of Organization, Functions, and Delegations of
Authority
Part C (Centers for Disease Control and Prevention) of the
Statement of Organization, Functions, and Delegations of Authority of
the Department of Health and Human Services (45 FR 67772-76, dated
October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as
amended most recently at 75 FR 34465, dated June 9, 2010) is amended to
reflect the substructure of the National Center for Emerging and
Zoonotic Infectious Diseases, Office of Infectious Diseases, Centers
for Disease Control and Prevention.
Section C-B, Organization and Functions, is hereby amended as
follows:
After the title and functional statements for the National
Center for Immunization and Respiratory Diseases (CVG), insert the
following:
National Center for Emerging and Zoonotic Infectious Diseases
(CVL). The National Center for Emerging and Zoonotic Infectious
Diseases (NCEZID) works to prevent and control a broad range of
infectious diseases through public leadership, partnerships,
science, and systems. In carrying out these activities, NCEZID: (1)
Works collaboratively across CDC and with external partners to
conduct, coordinate, support, and evaluate public health efforts to
prevent and minimize morbidity and mortality due to infectious
diseases, promoting a One Health approach involving the interface of
animal, human, and environmental factors; (2) develops, evaluates,
and advances science, programs, management, and operations toward
meeting the agency's infectious disease related mission and goals;
(3) conducts epidemiologic and laboratory science and applied
research aimed at identifying risk factors and disease burdens and
developing and implementing public health programs, practices, and
policies for infectious disease prevention and control; (4) works
with domestic and global partners to provide technical and subject
matter expertise in responding to outbreaks and in establishing,
maintaining, and evaluating disease control and prevention programs;
(5) supports a broad range of cross-cutting and collaborative
programs aimed at enhancing public health capacity at the local,
State, and national levels; (6) works to improve the quality and
safety of healthcare through efforts to reduce healthcare associated
infections and antimicrobial resistance and to ensure the safety of
medical products, including vaccines; (7) conducts activities to
improve the safety of food and water and reduce related enteric
illnesses; (8) administers a national quarantine program to prevent
U.S. importation and spread of infectious diseases; (9) works with
CDC colleagues and external partners to improve public health
preparedness at the local, State, and national levels; and (10)
works to increase public health prevention efforts for populations
at increased risk for infectious diseases.
Office of the Director (CVL1). (1) Provides leadership in
developing, prioritizing, advancing, and evaluating the center's
science, programs, management, and operations toward meeting agency
mission and goals; (2) advises the CDC Director and Deputy Director
for Infectious Diseases on priority issues affecting the center; (3)
identifies and facilitates synergies within NCEZID, across CDC, and
with external partners for addressing emerging and zoonotic
infectious diseases domestically and globally; (4) enhances
collaborations and partnerships across multiple disciplines,
including human and animal health; (5) ensures scientific quality
and ethical and regulatory compliance of center activities; (6)
provides leadership, guidance, and technical assistance on policy
and communication issues affecting the center; (7) serves as liaison
with CDC counterparts, CDC/OD, other government agencies, and
external partners on policy, program, legislative, communication,
and budgetary issues related to NCEZID; (8) recruits and supports a
strong center-wide workforce and builds leadership at the division
and branch levels; (9) ensures that programmatic goals are achieved
with measurable impact; and (10) ensures effective administrative
services for NCEZID as well as effective cross-cutting scientific
and program services for all CDC's infectious disease national
centers.
Food Safety Office (CVL12). (1) Provides leadership in
preventing and controlling foodborne illness by coordinating related
activities within CDC and with other local, State, Federal, and
international organizations; (2) directs the activities related to
development of long-term NCEZID, OID, and CDC strategies, policies,
and budgets for foodborne disease prevention activities; (3)
allocates and tracks interagency resources within CDC for foodborne
disease surveillance, outbreak response, applied research, education
and training; (4) administers and tracks resources for foodborne
disease prevention and control activities of State and local health
departments and other organizations; (5) represents NCEZID and CDC
programs and prevention policies in meetings with governmental, non-
governmental, private, and international organizations; (6) reviews,
prepares, and coordinates congressional testimony and briefing
documents related to foodborne diseases, and analyzes programmatic
and policy implications of legislative proposals; and (7) provides
direction and administrative support to the World Health
Organization (WHO) Collaborating Center for Foodborne Disease
Surveillance.
Division of Foodborne, Waterborne, and Environmental Diseases
(CVLB). The mission of the Division of Foodborne, Waterborne, and
Environmental Diseases (DFWED) is to improve public health
nationally and internationally through the prevention and control of
disease, disability, and death caused by foodborne, waterborne, and
environmentally-transmitted infections. In carrying out its mission,
DFWED: (1) Conducts surveillance, investigations, and studies of
foodborne bacterial diseases, waterborne bacterial and parasitic
diseases, and mycotic diseases to define disease etiology and
develop effective methods for diagnosis, prevention, and control;
(2) conducts or participates in clinical, field, and laboratory
research to develop, evaluate, and improve laboratory methodologies,
materials, and therapeutic practices used for environmental
detection, diagnosis, treatment, investigation, and control of
foodborne bacterial diseases, waterborne bacterial and parasitic
diseases, and mycotic diseases; (3) fosters and coordinates
environmental microbiology research activities at CDC through the
Environmental Microbiology Workgroup, partnerships, and advocacy
activities to promote research on preventing infectious disease
transmission from the environment to humans; (4) provides epidemic
aid and epidemiologic consultation, upon request, to State and local
health departments, other Federal agencies, and national and
international health organizations; (5) provides reference/
diagnostic services for foodborne bacterial diseases, waterborne
bacterial and parasitic diseases, and mycotic diseases to State and
local health departments, other Federal agencies, and national and
international health organizations; (6) provides scientific and
technical assistance to other CDC components when the work requires
unique expertise or specialized equipment not available in other
components; (7) provides intramural and extramural technical
expertise and assistance in professional training and proficiency
testing activities; (8) serves as appropriately designated national
and international reference centers for various foodborne bacterial
diseases, waterborne bacterial and parasitic diseases, and mycotic
diseases and disease groups; and (9) develops clear health promotion
strategies, campaigns, and messages to promote prevention.
Office of the Director (CVLB1). (1) Directs and manages the
programs and activities of DFWED; (2) provides leadership and
guidance on policy, program planning and development, program
management, and operations; (3) coordinates or assures coordination
with the appropriate CDC and
[[Page 43191]]
NCEZID offices on administrative and program matters; (4) reviews,
prepares, and coordinates congressional testimony and briefing
documents related to foodborne bacterial diseases, waterborne
bacterial and parasitic diseases, and mycotic diseases, and analyzes
programmatic and policy implications of legislative proposals; (5)
represents CDC and NCEZID programs and prevention policies in
meetings with governmental, private, and international
organizations; (6) advises CDC and NCEZID on policy matters
concerning DFWED programs and activities; (7) provides statistical
methodology and participates in the DFWED's outbreak investigations
and disease reporting systems for ongoing surveillance; (8) develops
new methods or adapts existing methods for statistical applications
in epidemiologic or laboratory research studies for the division;
(9) provides statistical consultation for epidemiologic and
laboratory research studies conducted by the division; (10) assists
researchers with statistical aspects of report writing and prepares
statistical portions of papers, protocols, and reports written by
staff of the division, and trains division professional staff in
statistical methods; (11) provides oversight for CDC involvement in
the WHO Global Foodborne Infections Network and training in food,
water, and zoonotic infection control and prevention; and (12)
provides subject matter expertise on environmental research, and
promotes and coordinates related research activities at CDC and with
collaborative partners.
Division of Global Migration and Quarantine (CVLC). (1)
Administers a national quarantine program to protect the U.S.
against the introduction of diseases from foreign countries and the
transmission of communicable disease between states; (2) administers
an overseas program for the medical examination of immigrants,
refugees, and as necessary, other migrant populations destined for
legal entry to the U.S., with inadmissible health conditions that
would pose a threat to public health and impose a burden on public
health and hospital facilities; (3) conducts surveillance, research,
and prevention programs to prevent minimize morbidity and mortality
among the globally mobile populations entering and leaving the U.S.;
(4) maintains liaison with other Federal agencies, State and local
health departments, and other stake holders, and provides
information on global migration and quarantine matters to them; (5)
provides liaison with international health organizations and
participates in the development of international agreements
affecting quarantine; (6) evaluates and provides technical support
on the development and enforcement of policies necessary for
implementation of Federal quarantine authority; (7) conducts studies
to provide new information about health hazards abroad, measures for
their prevention, and the potential threat of disease introduction
into the U.S.; and (8) provides logistic support to other programs
of the CDC in the distribution of requested biological agents and
movement of biological specimens through U.S. ports of entry.
Office of the Director (CVLC1). (1) Manages, directs, and
coordinates the activities of the division; (2) provides leadership
in development of division policy, program planning, implementation,
and evaluation; (3) identifies needs and resources for new
initiatives and assigns responsibilities for their development; (4)
coordinates liaison with other Federal agencies, State and local
health departments, and interested industries; (5) coordinates
liaison with international health organizations; and (6) reviews and
evaluates all administrative services for both headquarters and
quarantine stations and provides policy procedures and guidance on
such matters.
Division of Healthcare Quality Promotion (CVLD). The mission of
the Division of Healthcare Quality Promotion (DHQP) is to protect
patients; protect healthcare personnel; and promote safety, quality,
and value in both national and international healthcare delivery
systems. In carrying out its mission, DHQP: (1) Measures, validates,
interprets, and responds to data relevant to healthcare processes
and outcomes, healthcare-associated infections, antimicrobial
resistance, adverse drug events, and other related adverse events or
medical errors in healthcare affecting patients and healthcare
personnel; (2) investigates and responds to emerging infections and
related adverse events among patients and healthcare providers, or
others associated with the healthcare environment; (3) collaborates
with academic and public health partners to design, develop, and
evaluate the efficacy of interventions for preventing infections and
reducing antimicrobial resistance, and related adverse events or
medical errors; (4) develops and disseminates evidence-based
guidelines and recommendations to prevent and control healthcare-
associated infections/antimicrobial resistance, and related adverse
events or medical errors; (5) promotes the nationwide implementation
of Healthcare Infection Control Practices Advisory Committee
(HICPAC) recommendations and other evidence based interventions to
prevent healthcare-associated infections, antimicrobial resistance,
and related adverse events or medical errors among patients and
healthcare personnel; evaluates the impact of these recommendations
and interventions across the spectrum of healthcare delivery sites;
(6) monitors vaccine safety and conducts scientific research to
evaluate the safety of all currently available and new vaccines; (7)
develops, implements, and evaluates the effectiveness and impact of
interventions to prevent transmission of healthcare-associated human
immunodeficiency virus (HIV) and other bloodborne pathogen
infections; (8) develops and evaluates diagnostic instruments and
novel laboratory tests to detect and characterize antimicrobial-
resistant bacterial pathogens and the infections that they cause;
(9) promotes high standards of water quality in healthcare settings
and tests and assures the water quality for CDC's infectious disease
laboratories; (10) conducts epidemiologic, and basic and applied
laboratory research to identify new strategies to prevent
infections/antimicrobial resistance, and related adverse events or
medical errors, especially those associated with medical or surgical
procedures, indwelling medical devices, contaminated products,
dialysis, and water; (11) establishes evidence-base for surface
decontamination by performing laboratory research on methods for
surface sampling detection of selected organisms related to
preventing healthcare associated infections; (12) serves as the
National Reference Laboratory for the identification and
antimicrobial susceptibility testing of staphylococci, anaerobic
bacteria, non-tuberculous mycobacterial, and those gram-negative
bacilli causing healthcare associated infections; (13) develops and
maintains the National Healthcare Safety Network (NHSN), a tool for
monitoring healthcare-associated infections, measuring healthcare
outcomes and processes, and monitoring healthcare worker vaccination
and selected health measures in healthcare facilities; (14)
continually assesses rates of infections caused by resistant-
bacteria in the U.S. through active surveillance, review of national
healthcare data sets, and laboratory surveillance programs; (15)
promotes the integration of the healthcare delivery system in
Federal/State/local public health preparedness planning; (16)
coordinates activities, guidance, and research related to infection
control across the agency and with national and international
partners; (17) collaborates with other CDC Centers/Institute/Offices
(CIO) and partners to assure quality clinical microbiology
laboratory practices through proficiency testing, educational
programs, and training of personnel; (18) trains Epidemic
Intelligence Service Officers and other trainees; (19) coordinates
antimicrobial resistance activities at CDC; (20) works in a national
leadership capacity with public and private organizations to enhance
antimicrobial resistance prevention and control, surveillance and
response, and applied research; and (21) coordinates blood, organ,
and other tissue safety at CDC.
Office of the Director (CVLD1). (1) Manages, directs, and
coordinates the activities of the DHQP; (2) provides leadership and
guidance on policy, communications/media, program planning and
development, program management, and operations; (3) provides DHQP-
wide administrative and program services and coordinates or ensures
coordination with the appropriate CIOs and CDC staff offices on
administrative and program matters; (4) provides liaison with other
governmental agencies, international organizations, and other
outside groups; (5) coordinates, in collaboration with the
appropriate CIO and CDC components, global health activities
relating to the prevention of healthcare-associated infections/
antimicrobial resistance, and related adverse events or medical
errors; (6) coordinates activities, guidance, emergency response,
and research related to infection control in healthcare settings
across the agency and with national and international partners; (7)
works with other Federal agencies, State governments, medical
societies, and other public and private organizations to promote
collaboration and to integrate healthcare preparedness in Federal/
State/local public
[[Page 43192]]
health preparedness planning; (8) oversees the coordination of
antimicrobial resistance activities at CDC; (9) represents CDC as
co-chair of the Federal Interagency Task Force on Antimicrobial
Resistance; (10) coordinates with other agencies, State governments,
medical societies, and other public and private organizations to
enhance antimicrobial resistance prevention and control,
surveillance and response, and applied research; (11) leads CDC's
activities on blood, organ, and other tissue safety; (12) represents
CDC on the Advisory Committee on Blood Safety and Availability and
the Advisory Committee on Organ Transplantation; (13) works with
other Federal agencies, State governments, and other public and
private organizations to enhance blood, organ, and other tissue
safety through coordination of investigation, prevention, response,
surveillance, applied research, health communication, and public
policy; (14) provides program and administrative support for HICPAC;
and (15) advises the Director, NCEZID, on policy matters concerning
DHQP activities.
Immunization Safety Office (CVLD12). (1) Assesses the safety of
vaccines received by children, adolescents and adults; (2)
coordinates vaccine safety activities at CDC; (3) monitors safety of
new and currently available vaccines; (4) coordinates and maintains
the Vaccine Adverse Event Reporting System and Vaccine Safety
Datalink; (5) leads CDC' s scientific research to evaluate the
safety of all currently available and new vaccines; and (6) works
with other Federal agencies, State governments, and other public and
private organizations to assess and promote the safety of vaccines.
Division of High-Consequence Pathogens and Pathology (CVLE). The
Division of High-Consequence Pathogens and Pathology (DHCPP)
maximizes public health and safety nationally and internationally
through the diagnosis, prevention, and control of disease,
disability, and death caused by suspected and known viral,
bacterial, prion, and related infections. In carrying out its
mission, DHCPP: (1) Conducts surveillance, investigations, and
studies of viral and bacterial diseases, including bioterrorism
agents, as well as of transmissible spongiform encephalopathies, or
prion diseases, and severe diseases of unknown, but suspected
infectious etiology, to define their etiology and epidemiology, and
to develop effective methods for diagnosis, treatment, control, and
prevention; (2) conducts or participates in clinical, field, and
laboratory research to develop, evaluate, and improve laboratory
methods, materials, and therapeutic practices used for diagnosis,
treatment, control, and prevention of viral, bacterial, and prion
diseases, including bioterrorism agents; (3) conducts research on
virus and bacterial transmission to develop effective control and
prevention strategies and on vaccine effectiveness to assess
prevention potential; (4) conducts laboratory, clinical, and
epidemiologic studies of highly hazardous disease agents that
require biosafety level 3 or biosafety level 4 security for their
safe handling; (5) conducts ecological studies to develop and
evaluate disease control and prevention measures; (6) provides
epidemic aid, epidemiologic consultation, reference and diagnostic
services, and technical assistance to State and local health
departments, other Federal agencies, and national and international
health organizations; (7) provides scientific and technical
assistance to other CDC components when the work requires unique
expertise or specialized equipment not available in other
components; (8) provides routine and specialized laboratory training
in the diagnosis, isolation, and characterization of viral and
bacterial agents to personnel from State and local health
departments and other national and international organizations; (9)
provides training opportunities for EIS officers and others in CDC
sponsored programs, including postgraduate students, postdoctoral
fellows, and other public health and laboratory scientists; (10)
provides expert pathological support for various infectious diseases
to other groups at CDC, State and local health departments, other
Office of Infectious Diseases (OID) components, and national and
international organizations; and (11) serves as appropriately
designated national and WHO Collaborating Centers for viral and
bacterial diseases.
Office of the Director (CVLE1). (1) Directs and manages the
programs and activities of DHCPP; (2) provides leadership and
guidance on policy, program planning and development, program
management, and operations; (3) coordinates or assures coordination
with the appropriate CDC, OID, and NCEZID offices on administrative
and program matters; (4) reviews, prepares, and coordinates
congressional testimony and briefing documents related to high-
consequence viral, bacterial, and prion diseases, and analyzes
programmatic and policy implications of legislative proposals; (5)
represents CDC, OID, and NCEZID programs and prevention policies in
meetings with other governmental, private, and international
organizations; (6) serves as CDC, OID, and NCEZID's primary internal
and external communications contact regarding high consequence
viral, bacterial, and prion disease issues; and (7) advises CDC,
OID, and NCEZID on policy matters concerning DHCPP programs and
activities.
Prion and Public Health Office (CVLE12). (1) Serves as the lead
Federal office for monitoring the occurrence of human prion disease
in the U.S.; (2) conducts epidemiological investigations, studies,
and multiple methods of surveillance to increase understanding of
human prion diseases and selected diseases of unknown etiology
(e.g., Kawasaki syndrome) for the purpose of informing disease
control policies; (3) facilitates the study of brain autopsies by
skilled pathologists of clinically diagnosed and suspected cases of
human prion disease in the U.S. to enable early recognition of the
emergence of any new prion disease (e.g., variant Creutzfeldt-Jacob
Disease and possibly human chronic wasting disease); (4) provides
prion disease consultations to clinicians, State and local health
departments, other Federal agencies, and national and international
organizations, including epidemic aid support as needed; (5)
disseminates information and advice to the public on preventing or
reducing the negative public impacts of prion diseases and selected
diseases of unknown etiology; (6) serves as a DHCPP statistical
analysis unit, collaborating with and supporting studies,
investigations, and surveillance activities of epidemiologists and
laboratory researchers; (7) provides statistical consultations and
collaborates with researchers on local, national, and international
public health morbidity and mortality studies that require expertise
in manipulating and understanding large public health datasets; and
(8) provides statistical and epidemiologic training opportunities
for EIS officers and other personnel in CDC sponsored programs.
One Health Office (CVLE13). (1) Serves as the agency focal point
and provides the programmatic home for activities on One Health, an
integrated approach to optimizing human and animal health that
considers the interrelatedness among humans, animals, and their
environments; (2) builds and organizes a portfolio of One Health
activities, plans, and accomplishments and leads the efforts to
promote and accomplish the activities through NCEZID and CDC
programs and partnerships; (3) builds partnerships and facilitates
collaboration both within and external to CDC; (4) manages and
allocates NCEZID extra-budgetary resources from the Department of
State/USAID, the Department of Defense/BTEP, the National Center for
Environmental Health/Climate Change, and others, as appropriate; and
(5) facilitates the exchange of information and enhances
communication across disciplines by sponsoring visiting scientists
and fellows, lectures, and meetings.
Division of Preparedness and Emerging Infections (CVLG). The
Division of Preparedness and Emerging Infections (DPEI) works to
build and strengthen public health capacity by enhancing the ability
of CDC and its public health partners to prepare for, prevent, and
respond to infectious diseases, including outbreaks, bioterrorism,
and other public health emergencies, through cross-cutting and
specialized programs, technical expertise, and public health
leadership. In carrying out these activities, the DPEI: (1)
Advocates for CDC programs, health departments, and other partners
on issues related to emerging infections, bioterrorism, and public
health resources; (2) develops and implements infectious disease
surveillance, laboratory, and capacity building activities in
collaboration with other CDC programs and external partners; (3)
works with infectious disease programs on processes for developing,
awarding, managing, and evaluating infectious disease grants and
cooperative agreements; (4) provides scientific and programmatic
leadership, as well as management, administrative, and technical
support for broad infectious disease cooperative agreements such as
the Emerging Infections Program (EIPs) and the Epidemiology and
Laboratory Capacity for Infectious Diseases (ELC) program; (5)
collaborates across CDC and with national and international partners
to address the scientific and response planning and preparedness
issues for bioterrorism, emerging infections, and other infectious
[[Page 43193]]
disease emergencies; (6) provides the agency's initial rapid
response capabilities (including 24 hour on-call emergency response
coordination and epidemiologic and laboratory support) for
bioterrorism and other infectious disease public health emergencies;
(7) conducts, supports, and evaluates activities aimed at
identifying and reducing risk factors for infectious diseases among
residents of the Arctic and Subarctic regions; (8) maintains primary
responsibility for development and management of the nation's
Laboratory Response Network (LRN), including supporting the
development, deployment, and quality control of diagnostic reagents
for the LRN laboratories; (9) defines and promotes good laboratory
practice standards, including providing consultation and training
and improving communication and collaborations among public and
private sector laboratories nationally and internationally; (10)
serves as a primary screening laboratory for CDC for specimens that
may contain threat agents; (11) analyzes the economic impact of
infectious diseases in collaboration with other CDC infectious
disease programs and collaborators outside the agency; (12) leads
and coordinates infectious disease fellowships and training
programs; (13) provides technical assistance and training on
biosafety/biosecurity and bioterrorism agent detection and response
to internal and external partners, including assistance with related
public health and law enforcement investigations and planning for
high profile national and international events; and (14) assists in
medical countermeasures response and utilization coordination.
Office of the Director (CVLG1). (1) Manages, directs, and
coordinates the activities of DPEI; (2) provides leadership and
guidance on division policy, program planning, program management,
and operations; (3) provides division-wide administrative and
program services and ensures coordination with the appropriate CIO
or staff offices on administrative and program matters; (4) provides
liaison with other governmental agencies, international
organizations, academic institutions and other outside groups; (5)
ensures coordination of cross-cutting division activities with
appropriate NCEZID divisions, the Office of Public Health
Preparedness and Response, the Office of Surveillance, Epidemiology,
and Laboratory Services (OSELS), and other CDC CIOs and offices; and
(6) advises the NCEZID Director, the Deputy Director for Infectious
Diseases, and leadership in other CDC units on division policy
matters.
Division of Scientific Resources (CVLH). The Division of
Scientific Resources (DSR) provides products, services, and
specialized expertise to CDC staff and activities in support of
research and service activities. In carrying out its mission, DSR:
(1) Provides animals, laboratory supplies, animal and human blood
products, glassware, mammalian tissue cultures, microbiological
media, special reagents, and other laboratory materials in support
of research and service activities to laboratories and investigators
at CDC; (2) develops and implements applied research programs to
expand and enhance the use of animal models necessary to support
research and diagnostic programs and to improve breeding and
husbandry procedures; (3) conducts applied research in cell biology
and in the expansion of tissue culture technology as a research and
diagnostic tool for infectious disease activities; (4) provides
services for laboratory investigators in protein and DNA synthesis
and sequencing, genomic sequencing, microarrays, proteomics, and
molecular modeling; (5) maintains a bank of serum and other
biological specimens of epidemiological and special significance to
CDC's research and diagnostic activities; (6) obtains and
distributes experimental and orphaned vaccines, drugs, antisera,
antitoxins, and immune globulins; (7) manages and distributes the
inventory, maintains the computerized system database, and provides
general technical service support for the dispensing, lyophilizing,
capping, and labeling of CDC reference reagents; (8) receives,
triages, processes, and distributes specimens to CDC laboratories
for reference diagnostic testing, research studies, and epidemics
and reports diagnostic test results to submitting organizations; (9)
manages all CDC exports and ensures compliance with regulations and
serves as CDC liaison with Department of Commerce for export related
issues; (10) produces and distributes specialized reagents and kits
for the detection of select agents to members of the LRN; (11)
provides services and expertise in development of quality systems to
support compliance with the Food and Drug Administration regulations
on production, distribution, and use of laboratory diagnostic
reagents; (12) provides liaison activities, resources, and expertise
for inquiries related to animals and zoonotic diseases; and (13)
provides a centralized activity for tracking requests for and
distributing select agents to investigators outside of CDC in
compliance with Federal regulations.
Office of the Director (CVLH1). (1) Manages, directs, and
coordinates the activities of DSR; (2) provides leadership and
guidance on policy, budget, program planning and development,
program management, and operations; (3) provides DSR wide
administrative and program services and coordinates or ensures
coordination with the appropriate CIOs OID, and CDC staff offices on
administrative and program matters; (4) provides liaison with other
governmental agencies, international organizations, and other
outside groups; (5) coordinates, in collaboration with the
appropriate CIOs, OID, and CDC components, laboratory activities
relating to support of outbreak investigations or laboratory-based
research including but not limited to specimen management,
biological reagents, and laboratory supplies; (6) maintains a
formulary of investigational and licensed drugs and biologicals that
are distributed to approved physicians for the prevention, control,
and/or treatment of rare, tropical, or exceptional diseases; (7)
collaborates with CDC and external partners on research related to
STD transmitted infections as chronic infectious diseases; and (8)
advises the Director, NCEZID, on policy matters concerning DSR
activities.
Division of Vector-Borne Diseases (CVLJ). (1) Conducts
surveillance, investigations, and studies of vector-borne viral,
rickettsial, and bacterial diseases to define disease etiology and
to develop effective methods and strategies for diagnosis,
prevention, and control; (2) conducts investigations on the biology,
ecology, and control of arthropod vectors of viral, rickettsial, and
bacterial diseases as a basis for development of new and/or
modification of existing measures for more effective prevention and
control; (3) conducts or participates in clinical, field, and
laboratory studies to develop, evaluate, and improve laboratory
methods, materials, and therapeutic practices used for diagnosis,
prevention, and treatment of vector-borne infectious diseases; (4)
provides epidemic aid and epidemiologic consultation, upon request,
to State and local health departments, other Federal agencies, and
national and international health organizations; (5) provides
reference/diagnostic services for vector-borne viral, rickettsial,
and bacterial diseases to State and local health departments, other
Federal agencies, and national and international health
organizations; (6) conducts research and collaborates on development
and evaluation of vaccines; (7) provides scientific and technical
assistance to other CDC components when the work requires unique
expertise or specialized equipment not available in other
components; (8) provides intramural and extramural technical
expertise and assistance in professional training activities; and
(9) serves as designated national and international reference
centers for vector-borne viral, rickettsial, and bacterial diseases.
Office of the Director (CVLJ1). (1) Directs and manages the
programs and activities of the Division of Vector-Borne Diseases
(DVBD); (2) provides leadership and guidance on policy, program
planning and development, program management, and operations; (3)
coordinates or assures coordination with the appropriate CDC, OID,
and NCEZID offices on administrative and program matters; (4)
reviews, prepares, and coordinates congressional testimony and
briefing documents related to vector-borne infectious diseases, and
analyzes programmatic and policy implications of legislative
proposals; (5) represents CDC and NCEZID in meetings with other
governmental, private, and international organizations; (6) serves
as CDC and NCEZID's primary internal and external communications
contact regarding vector-borne infectious disease issues; and (7)
advises CDC and NCEZID on policy matters concerning DVBD programs
and activities.
Dated: July 9, 2010.
William P. Nichols,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2010-17794 Filed 7-22-10; 8:45 am]
BILLING CODE 4160-18-M